Neuromuscular Disease News

In this video David Lynch, MD, PhD, discusses the effect Friedreich's ataxia can have on patients' quality of life.

In this video David Lynch, MD, PhD, highlights one of the greatest unmet needs in Friedreich's ataxia management.

In this video David Lynch, MD, PhD, emphasizes the need for Friedreich's ataxia awareness.

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and older with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.

In this video David Lynch, MD, PhD, discusses current treatment options for Friedreich's ataxia patients.

The FDA has approved Ctexli for the treatment of cerebrotendinous xanthomatosis (CTX), a rare lipid storage disease, in adults.

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more than 44 pounds, according to the manufacturer.

Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone treatment, results of an administrative claims analysis show.

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully human monoclonal antibody to treat individuals with spinal muscular atrophy.